Alembic Q2 sales up 13%; eyes derisked manufacturing
This article was originally published in Scrip
Executive Summary
Alembic Pharmaceuticals has reported a 13% increase in revenues to INR5.48bn ($89.4m) for the second quarter ended 30 September 2014, backed by the strong showing of its branded formulations business in India. Net profits for the quarter were up 25% INR773m.